Ascierto PA, et al. - In patients with previously untreated BRAF wild-type advanced melanoma, researchers compared the 3-year survival with nivolumab vs that with dacarbazine in this follow-up of a randomized phase 3 trial. Patients were enlisted from January 2013 through February 2014 for this ongoing, multicenter academic institution trial. In patients with previously untreated BRAF wild-type advanced melanoma, nivolumab led to improved 3-year overall survival compared to dacarbazine. There were no deaths from the toxic effects of the drug study.